MARKET

CDXC

CDXC

ChromaDex
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.04
+0.41
+4.75%
After Hours: 9.04 0 0.00% 16:41 07/28 EDT
OPEN
8.75
PREV CLOSE
8.63
HIGH
9.30
LOW
8.74
VOLUME
288.51K
TURNOVER
--
52 WEEK HIGH
23.66
52 WEEK LOW
3.820
MARKET CAP
614.11M
P/E (TTM)
-26.3711
1D
5D
1M
3M
1Y
5Y
Analysts Estimate ChromaDex (CDXC) to Report a Decline in Earnings: What to Look Out for
Zacks.com · 1d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Benzinga · 5d ago
ChromaDex Corporation's (NASDAQ:CDXC) Intrinsic Value Is Potentially 27% Above Its Share Price
How far off is ChromaDex Corporation ( NASDAQ:CDXC ) from its intrinsic value? Using the most recent financial data...
Simply Wall St. · 07/11 08:11
ChromaDex rises after NIAGEN-component shows promise in COVID-19 trial
Ilya S. Savenok/Getty Images Entertainment ChromaDex ([[CDXC]] +8.6%) has added nearly a tenth by afternoon trading after a Phase 3 clinical trial showed that a mix of metabolic activators including
Seekingalpha · 06/28 18:06
Watching ChromaDex Shares As Traders Circulate Study 'Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19'
https://onlinelibrary.wiley.com/doi/10.1002/advs.202101222https://onlinelibrary.wiley.com/doi/10.1002/advs.202101222<
Benzinga · 06/28 17:19
Supplements company ChromaDex drops after new short call from J Capital Research
Supplements maker ChromaDex (CDXC) fell 1.6% in premarket trading after a report from short seller J Capital Research claims that the company is "pure hype."J Capital questions the background of some
Seekingalpha · 06/24 11:16
CHROMADEX'S HEALTHY AGING PRODUCTS GAIN NEW TRACTION WITH FOUR HUGE DISTRIBUTION AGREEMENTS INCLUDING WALMART
ChromaDex Corp. (NASDAQ: CDXC) participated in a virtual presentation at the Benzinga Small Cap Conference in May 2021. ChromaDex CEO Rob Fried also presented on a panel discussing "Investing in Longevity Science: The New Drugs & Therapies Designed to Prol...
Benzinga · 06/16 14:35
BRIEF-ChromaDex Shares Research Findings From The Chromadex External Research Program
reuters.com · 06/16 11:45
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CDXC. Analyze the recent business situations of ChromaDex through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CDXC stock price target is 15.00 with a high estimate of 18.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 118
Institutional Holdings: 22.70M
% Owned: 33.42%
Shares Outstanding: 67.93M
TypeInstitutionsShares
Increased
23
3.72M
New
28
6.68M
Decreased
33
2.84M
Sold Out
16
1.44M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.51%
Pharmaceuticals & Medical Research
+1.83%
Key Executives
Chairman/Executive Director
Frank Jaksch
Chief Executive Officer/Director
Robert Fried
Chief Financial Officer
Kevin Farr
Chief Marketing Officer
Fadi Karam
General Counsel/Secretary
Lisa Harrington
Lead Director/Independent Director
Kurt Gustafson
Independent Director
Jeffrey Baxter
Independent Director
Stephen Block
Independent Director
Tony Lau
Independent Director
Steven Rubin
Independent Director
Wendy Yu
No Data
About CDXC
Chromadex Corporation is an integrated nutraceutical company. The Company and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provides research and quality-control products and services to the natural products industry. The Company partners with universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of nicotinamide adenine dinucleotide (NAD) and its impact on human health. The Company’s operated segments are: Consumer Product, Ingredients, and Analytical Reference Standards and Service Segment. Its Consumer Product segment offers TRU NIAGEN to consumers worldwide. Its ingredients business segment develops and commercializes ingredients, including nicotinamide riboside (NR), for which its brand name is NIAGEN. It also develops pterostilbene, which is marketed and sold under its brand name, pTeroPure.

Webull offers kinds of Chromadex Corp stock information, including NASDAQ:CDXC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDXC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CDXC stock methods without spending real money on the virtual paper trading platform.